Literature DB >> 10072026

The anesthetic and physiologic effects of an intravenous administration of a halothane lipid emulsion (5% vol/vol)

J B Musser1, J L Fontana, P D Mongan.   

Abstract

UNLABELLED: The i.v. administration of < or = 9 mL of nonvaporized liquid halothane causes significant pulmonary damage, cardiovascular decompensation, and death. To determine whether liquid halothane mixed in a lipid emulsion would alter these toxic effects, six swine were evaluated in a randomized cross-over study. The pulmonary, analgesic, hemodynamic, and histopathologic effects of liquid halothane (25 mL) mixed with a liquid carrier (475 mL, Liposyn III 20%) and administered by constant infusion were compared with halothane administered by a calibrated vaporizer. Three swine received the halothane lipid emulsion (HLE), followed by inhaled halothane. Three additional swine received inhaled halothane, followed by the HLE. There were no changes in pulmonary compliance or arterial blood gases during or after the administration of equivalent volumes of halothane (13.75 mL) either by infusion of HLE or by inhalation of halothane. The end-tidal halothane concentration for the minimum alveolar anesthetic concentration was 0.79% +/- 0.08% during HLE administration and 1.13% +/- 0.12% for inhaled halothane (P < 0.001). Hemodynamic variables and blood halothane levels by gas chromatography were measured at end-tidal concentrations of 0.6%, 1.2%, and 1.8%. Blood halothane levels (mg/mL) were significantly higher (P < 0.05) after the administration of HLE at end-tidal halothane concentrations of 1.2% (0.49 +/- 0.19 vs 0.82 +/- 0.18) and 1.8% (0.79 +/- 0.17 vs 1.29 +/- 0.34). When compared at equivalent blood levels, HLE caused fewer changes in the left ventricular end-diastolic pressure, mean arterial pressure, and dP/dt than inhaled halothane. There was no evidence of pulmonary histopathologic damage 4-8 h after the infusion of 500-700 mL of HLE. This novel method of delivery of a volatile anesthetic seems to lack the toxicity of direct i.v. administration of liquid halothane. It may be a useful alternative to traditional administration via a vaporizer. IMPLICATIONS: Halothane causes pulmonary dysfunction and death when given i.v. in liquid form. Six swine received a halothane lipid emulsion i.v. to evaluate the anesthetic and physiologic effects. No pulmonary toxicity or deaths were associated with the halothane lipid emulsion. The anesthetic profile was similar to delivery of halothane via a vaporizer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10072026     DOI: 10.1097/00000539-199903000-00038

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  6 in total

1.  Getting oil and water to mix.

Authors:  Evan D Kharasch
Journal:  Anesthesiology       Date:  2012-03       Impact factor: 7.892

Review 2.  Signaling epicenters: the role of caveolae and caveolins in volatile anesthetic induced cardiac protection.

Authors:  Yousuke T Horikawa; Yasuo M Tsutsumi; Hemal H Patel; David M Roth
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  Synthesis, emulsification and self-assembly properties of sugar-containing semifluorinated amphiphiles.

Authors:  Andrew V Razgulin; Sandro Mecozzi
Journal:  Carbohydr Res       Date:  2015-01-14       Impact factor: 2.104

4.  Exceptionally stable fluorous emulsions for the intravenous delivery of volatile general anesthetics.

Authors:  Jun-Pil Jee; Maria C Parlato; Mark G Perkins; Sandro Mecozzi; Robert A Pearce
Journal:  Anesthesiology       Date:  2012-03       Impact factor: 7.892

5.  Fluoropolymer-based emulsions for the intravenous delivery of sevoflurane.

Authors:  Jonathan P Fast; Mark G Perkins; Robert A Pearce; Sandro Mecozzi
Journal:  Anesthesiology       Date:  2008-10       Impact factor: 7.892

6.  [In-vivo diagnosis of malignant hyperthermia susceptibility: a microdialysis study].

Authors:  F Schuster; M Hager; T Metterlein; R M Muellenbach; T Wurmb; C Wunder; N Roewer; M Anetseder
Journal:  Anaesthesist       Date:  2008-08       Impact factor: 1.041

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.